Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas

Investing.com · 2026-11-06 11:53 UTC

Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas

Nov 6 (Reuters) - Moderna lifted its full-year revenue forecast on Friday, after strong international demand for its COVID-19 vaccine and payments from partnerships helped the biotech swing to profit in the third quarter.

The strong results provide fresh momentum for Moderna’s efforts to build a sustainable business through new products, including its newly approved flu vaccine and a personalized cancer vaccine candidate, which investors see as key to the long-term growth of its mRNA platform.

Moderna now expects total revenue to grow 15% to 25% in 2026, above its previous forecast of up to 10% growth.

Read the full story at Investing.com · All coverage of this story